Earlier this autumn, Abliva announced that NV354, the company's second candidate within the primary mitochondrial disease space, will progress to clinical phase. NV354 is initially being developed for the fatal Leigh syndrome, a disease that usually debuts before the age of 2 and patients often die before the age of 5. With NV354 about to join Abliva's leading candidate against primary mitochondrial disease, KL1333, in clinical development, BioStock takes a closer look at the candidate.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/